Clinical Trials Logo

Metastatic Thymic Carcinoma clinical trials

View clinical trials related to Metastatic Thymic Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT04710628 Active, not recruiting - Thymoma Type B3 Clinical Trials

Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents

PECATI
Start date: September 21, 2021
Phase: Phase 2
Study type: Interventional

This is a multicentric, open-label, single arm phase II study to evaluate the efficacy and safety of the combination of pembrolizumab and lenvatinib in pre-treated thymic carcinoma patients who have progressed after at least one line of platinum-based chemotherapy for advanced disease without having received any previous immunotherapy (previous bevacizumab allowed, but not sunitinib), and not amenable to curative-intent radical surgery and/or radiotherapy, regardless of PD-L1 status.

NCT ID: NCT04662645 Completed - Clinical trials for Stage IV Lung Cancer AJCC v8

Embedded Palliative Care in Managing Symptoms in Participants With Recurrent Stage III-IV Thoracic Malignancies and Their Caregivers

Start date: December 12, 2018
Phase: N/A
Study type: Interventional

This trial studies how well embedded palliative care works in managing symptoms in participants with stage III-IV thoracic malignancies that has come back and their caregivers. Embedded palliative care may improve distress and anxiety in participants and caregivers.

NCT ID: NCT03694002 Active, not recruiting - Clinical trials for Metastatic Thymic Carcinoma

Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

Start date: March 20, 2019
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well carboplatin and paclitaxel with or without ramucirumab work in treating patients with thymic cancer that has spread to other places in the body, has come back, or cannot be removed by surgery. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as ramucirumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known if giving carboplatin and paclitaxel with or without ramucirumab will work better in treating patients with thymic cancer.